ABCMdb

PMID: 21190282

Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A
Sterol transporter adenosine triphosphate-binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population.
Hepatology. 2010 Oct 20., 2010-10-20 [PubMed]

Sentences

No. Mutations Sentence Comment

1 ABCG8 p.Asp19His ABCG8 p.Asp19His To test the hypothesis that ABCG8 (adenosine triphosphate-binding cassette transporter G8) Asp19His (D19H) genotype predicted risk of gallstones and biliary cancer in the general population, we studied 62,279 white individuals from The Copenhagen City Heart Study and The Copenhagen General Population Study, randomly selected to reflect the adult Danish population aged 20 to 801 years. Login to comment 6 ABCG8 p.Asp19His The fraction of all gallstones attributed to D19H was 11%. Login to comment 8 ABCG8 p.Asp19His The fraction of all biliary cancers attributed to the D19H genotype was 27%. Login to comment 9 ABCG8 p.Asp19His Finally, D19H genotype associated with stepwise increases in plasma levels of alanine aminotransferase and gamma glutamyltransferase of up to 14% and 25% in HH homozygotes, and with corresponding stepwise reductions in plasma levels of total and low-density lipoprotein cholesterol of up to 5% versus noncarriers (all comparisons, P for trend <0.001). Login to comment 10 ABCG8 p.Asp19His Conclusion: In this general population cohort, ABCG8 D19H genotype was an important predictor of both symptomatic gallstone disease and biliary cancer. Login to comment 20 ABCG8 p.Asp19His 640 A recent genomewide association scan identified the sterol transporter adenosine triphosphate-binding cassette transporter G8 (ABCG8) as a susceptibility factor for gallstone disease in humans.6 The association was attributed to a common variant that leads to the substitution of aspartate with histidine at amino acid residue 19 (D19H; rs11887534). Login to comment 21 ABCG8 p.Asp19His ABCG8 p.Asp19His It has been hypothesized that D19H constitutes a gain-of-function variant that increases hepatobiliary cholesterol efflux, resulting in precipitation of cholesterol gallstones.6-8 Gallstone disease is a risk factor for biliary cancer, a rare but highly lethal disease.9 Whether D19H affects the risk of gallstone disease and biliary cancer in the general population is currently unknown. Login to comment 22 ABCG8 p.Asp19His This question is clinically important because (1) genetic variants identified in case-control studies often overestimate risk compared to studies of the general population10,11 ; (2) D19H has the potential to become the first lithogenic genetic variant included in presymptomatic genetic screening for gallstone disease and/or biliary cancer in the general population; and (3) the identification of specific genetic variants predisposing to gallstones and biliary cancer might also lead to new nonsurgical interventions that extend our current limited strategies for the prevention of these diseases. Login to comment 23 ABCG8 p.Asp19His We tested the clinical impact of the D19H genotype in 62,279 individuals from the Danish general population followed from January 1976 through May 2009, of whom 3124 developed symptomatic gallstone disease and 30 developed biliary cancer. Login to comment 25 ABCG8 p.Asp19His First, we determined whether D19H predicted risk of symptomatic gallstone disease and/or biliary cancer in the general population; on the basis of these results, we calculated the population-attributable risk. Login to comment 26 ABCG8 p.Asp19His Subsequently, we determined the absolute 10-year risk of symptomatic gallstone disease as a function of D19H genotype stratified by sex, age, and body mass index (BMI). Login to comment 27 ABCG8 p.Asp19His ABCG8 p.Asp19His Finally, to explore the effect of D19H genotype on liver and pancreas damage, and on the putative effects on cholesterol excretion, we determined the association of the D19H genotype with plasma liver biochemistry and with plasma lipid and lipoprotein levels. Login to comment 53 ABCG8 p.Asp19His An ABI-Prism 7900HT Sequence Detection System (Applied Biosystems) and a TaqMan-based assay was used to genotype for ABCG8 D19H (rs11887534). Login to comment 64 ABCG8 p.Asp19His For trend tests, subjects were classified according to D19H genotype and coded as 0 for noncarriers, 1 for heterozygotes and 2 for homozygotes. Login to comment 66 ABCG8 p.Asp19His Kaplan-Meier curves and log-rank tests evaluated the cumulative incidence of symptomatic gallstone disease and biliary cancer as a function of age and ABCG8 D19H genotype. Login to comment 75 ABCG8 p.Asp19His Interaction of D19H genotype with other risk factors for gallstones (age, sex, BMI, physical activity, parity, hormone replacement therapy, and alcohol intake) were evaluated by including two-factor interaction terms between genotype and other risk factors, one at a time, in the Cox regression model. Login to comment 76 ABCG8 p.Asp19His Population-attributable risk was calculated as previously described.18 Absolute 10-year risks for symptomatic gallstone disease by ABCG8 D19H genotype, age (<40 years, 40-60 years, >60 years), and BMI (<25 kg/m2 [normal], 25-30 kg/m2 [overweight], >30 kg/m2 [obese]) were estimated with the use of the regression coefficients from a Poisson regression model for women and men separately, and presented as estimated incidence rates (number of events per 10 years) in percent.19,20 Results Clinical Characteristics. Login to comment 82 ABCG8 p.Asp19His ABCG8 p.Asp19His Risk factors for symptomatic gallstone disease did not differ by D19H genotype, and were thus unlikely to confound any association of D19H with risk of symptomatic gallstone disease (compare Table 1 with Table 2). Login to comment 84 ABCG8 p.Asp19His The cumulative incidence of symptomatic gallstone disease as a function of age increased stepwise by D19H genotype, with HH homozygotes having the highest risk and DH heterozygotes an intermediate risk compared with noncarriers (Fig. 1; P for trend <0.001). Login to comment 87 ABCG8 p.Asp19His HRs for symptomatic gallstone disease as a function of D19H genotype in the general population adjusted for age and sex were 1.9 (95% confidence interval [CI], 1.7-2.1) for DH heterozygotes and 3.3 (95% CI, 2.34.6) for HH homozygotes compared with noncarriers (Fig. 1). Login to comment 89 ABCG8 p.Asp19His There were no significant interactions between D19H genotype and any of the abovementioned risk factors on risk of symptomatic gallstone disease. Login to comment 91 ABCG8 p.Asp19His The HR for cholecystectomy as a function of D19H genotype in the general population adjusted for age and sex was 2.0 (95% CI, 1.8-2.3) for DH heterozygotes and 3.3 (95% CI, 2.2-4.9) for HH homozygotes Table 1. Characteristics of Individuals in the General Population* by Disease Status Characteristic No event Gallstone Disease Biliary Cancer Number of individuals (%) 59,155 (95) 3124 (5) 30 (0.05) Age (years) 57 (46-66) 60 (50-70)‡ 66 (61-72)‡ Women (%) 54 72‡ 57 BMI (kg/m2 ) 25 (23-28) 27 (24-30)‡ 27 (25-29)§ Physical activity (%) 46 36‡ 27§ Mean parity (number of births)† 1.8 2.0‡ 1.4 Hormone replacement therapy (%)† 13 20‡ 18 Alcohol consumption (%) 49 40‡ 50 Lipid-lowering therapy (%) 8 11‡ 0 Values are median (interquartile range) or percentage. Physical activity was 4 hours or more per week of light physical activity in leisure time. Alcohol consumption was at least twice weekly. P values as calculated by Mann-Whitney U test or Pearson`s chi-square test. Login to comment 96 ABCG8 p.Asp19His Table 2. Characteristics of Individuals in the General Population* as a Function of ABCG8 D19H Genotype Characteristic DD Noncarriers DH Heterozygotes HH Homozygotes P Value Number of individuals (%) 54,526 (87.5) 7,506 (12.1) 247 (0.4) NA Age (years) 57 (46-67) 57 (47-67) 57 (45-68) 0.57 Women (%) 55 55 53 0.36 BMI (kg/m2 ) 26 (23-29) 26 (23-28) 26 (23-28) 0.83 Physical activity (%) 46 45 43 0.37 Mean parity (number of births)† 1.8 1.8 1.7 0.54 Hormone replacement therapy (%)† 14 13 11 0.71 Alcohol consumption (%) 48 49 48 0.72 Values are median (interquartile range) or percentage. Physical activity was 4 hours or more per week of light physical activity in leisure time. Alcohol consumption was at least twice weekly. P values as calculated by Kruskal-Wallis analysis of variance or Pearson`s chi-square test. Login to comment 100 ABCG8 p.Asp19His D19H genotype did not associate with overall mortality. Login to comment 101 ABCG8 p.Asp19His ABCG8 p.Asp19His Based on the frequency of D19H and the observed HRs for symptomatic gallstone disease as a function of genotype, the fraction of all gallstones that could be attributed to D19H was 11%. Login to comment 102 ABCG8 p.Asp19His Absolute 10-year risk of symptomatic gallstone disease increased from men to women, with increasing age, increasing BMI, and by D19H genotype (Fig. 2). Login to comment 106 ABCG8 p.Asp19His The cumulative incidence of biliary cancer as a function of age increased by D19H genotype (Fig. 3; P < 0.001). Login to comment 107 ABCG8 p.Asp19His The HR for biliary cancer as a function of D19H genotype adjusted for age and sex was 4.0 (95% CI, 1.9-8.4) for DH heterozygotes and HH homozygotes combined compared with noncarriers (Fig. 3) (3.8 [95% CI, 1.8-8.1] in DH heterozygotes and 10.3 [95% CI, 1.4-77.5] in HH homozygotes). Login to comment 110 ABCG8 p.Asp19His The fraction of all biliary cancers attributed to D19H was 27% (for clinical characteristics of patients, see Table 3). Login to comment 112 ABCG8 p.Asp19His D19H associated with stepwise increases in plasma levels of gamma glutamyltransferase and alanine aminotransferase of, respectively, 3% and 2% for heterozygotes, and 25% and 14% for homozygotes compared with noncarriers (Fig. 4; P for trend <0.001). Login to comment 113 ABCG8 p.Asp19His Alcohol intake was equally distributed among the different D19H genotypes and therefore did not confound these associations (Table 2). Login to comment 116 ABCG8 p.Asp19His D19H genotype associated with modest stepwise reductions in plasma levels of total cholesterol and LDL cholesterol of 1.6% and 2.4%, respectively, in DH heterozygotes, and of 3.5% and 4.5%, respectively, in homozygotes compared with noncarriers (Fig. 4; P for trend <0.001). Login to comment 120 ABCG8 p.Asp19His Cumulative incidence of symptomatic gallstone disease (graph at top) and mean age at onset (table at bottom) as a function of ABCG8 D19H genotype in the general population. Login to comment 124 ABCG8 p.Asp19His Absolute 10-year risk of developing gallstone disease as a function of ABCG8 D19H genotype, by sex, age (<40 years, 40-60 years, >60 years), and body mass index (<25 kg/m2 , normal weight; 25-30 kg/m2 , overweight; >30 kg/m2 , obese). Login to comment 127 ABCG8 p.Asp19His There was no association of D19H with HDL cholesterol or triglycerides. Login to comment 128 ABCG8 p.Asp19His Discussion The principal findings of this study of 62,279 individuals from the general population, of which 3124 developed symptomatic gallstone disease and 30 developed biliary cancer, are: (1) ABCG8 D19H genotype associated with an approximate 2-fold to 3.5-fold increase in risk of symptomatic gallstone disease in more than 12% of the general population. Login to comment 129 ABCG8 p.Asp19His (2) D19H genotype associated with stepwise reductions in mean age at onset of symptomatic gallstone disease of up to 4 years in homozygotes. Login to comment 130 ABCG8 p.Asp19His (3) A total of 11% of symptomatic gallstones in the general population could be attributed to D19H genotype. Login to comment 131 ABCG8 p.Asp19His (4) Heterozygous and homozygous carriers for D19H had a four-fold Fig. 3. Login to comment 132 ABCG8 p.Asp19His Cumulative incidence of biliary cancer in the general population as a function of ABCG8 D19H genotype. Login to comment 135 ABCG8 p.Asp19His Table 3. Characteristics of the 30 Participants With Biliary Cancer Subject Number D19H Genotype Sex (F/M) BMI (kg/m2) Age at Baseline Examination Age at Diagnosis of Gallstone Disease Age at Cholecystectomy Age at Diagnosis of Biliary Cancer ICD-10 Code Age at Death 1 HH F 28 62 77 77 C24.9 77 2 DH F 24 52 57 57 C24.0 58 3 DH F 24 62 59 74 C24.0 75 4 DH F 33 67 71 C24.9 71 5 DH M 31 68 81 C23.9 81 6 DH F 27 71 82 82 83 C24.8 83 7 DH M 29 72 79 C24.0 80 8 DH F 29 73 76 76 77 C24.1 77 9 DH F 30 78 79 79 79 C24.9 81 10 DH F 22 85 87 C23.9 87 11 DH M 28 87 91 C23.9 91 12 DD M 27 45 48 C24.0 51 13 DD F 38 45 61 C24.0 14 DD M 28 46 48 58 C24.0 58 15 DD F 31 50 51 51 C24.0 51 16 DD M 25 50 66 C24.9 17 DD M 25 54 69 70 C23.9 71 18 DD M 27 61 68 C24.0 68 19 DD F 30 61 67 67 C23.9 68 20 DD F 20 62 75 C24.9 77 21 DD M 26 63 79 C24.9 22 DD F 25 63 66 C23.9 66 23 DD F 26 64 72 72 C24.0 72 24 DD F 26 67 77 C23.9 78 25 DD F 26 69 80 C24.0 82 26 DD M 28 72 74 C22.1 74 27 DD F 38 72 78 C24.9 79 28 DD M 29 78 80 80 C24.1 80 29 DD M 24 81 82 C24.1 86 30 DD M 28 82 89 C23.9 90 BMI is in kg/m2 . Login to comment 140 ABCG8 p.Asp19His (5) A total of 27% of biliary cancers could be attributed to D19H. Login to comment 141 ABCG8 p.Asp19His (6) D19H genotype associated with stepwise increases in plasma alanine aminotransferase and gamma glutamyltransferase, and with a modest stepwise decrease in total and LDL cholesterol levels. Login to comment 143 ABCG8 p.Asp19His The incidence of symptomatic gallstone disease and biliary cancer, and the frequency of D19H, in our study are comparable to previous studies in Western countries.6,21,22 The incidence rates of mainly biliary cancer were lower in the CGPS compared to the CCHS. Login to comment 147 ABCG8 p.Asp19His Possible explanations for this include a higher background risk of biliary cancer in India than in Western countries,9,21 a different etiology (bacterial infection of bile), and a frequency of D19H among controls of 23%, which is twice that reported in Western populations. Login to comment 148 ABCG8 p.Asp19His We found that D19H associates with reductions in plasma total and LDL cholesterol levels. Login to comment 149 ABCG8 p.Asp19His ABCG8 p.Asp19His ABCG8 p.Asp19His In hepatocytes, ABCG8 forms half of a transmembrane sterol transporter that effluxes sterols into bile.27 Because biliary supersaturation with cholesterol is a pivotal event in cholesterol gallstone formation and D19H is associated with gallstones, it has been hypothesized that D19H constitutes a gain-of-function variant that increases biliary cholesterol efflux.6-8 Overexpression of ABCG8 in mice leads to reduced levels of plasma sterols.28 By analogy, a stepwise reduction in levels of plasma cholesterol as a function of D19H genotype in humans would support the gain-of-function hypothesis. Login to comment 151 ABCG8 p.Asp19His We detected a modest but statistically highly significant stepwise reduction in plasma LDL cholesterol levels as a function of D19H genotype. Login to comment 154 ABCG8 p.Asp19His We found a modest stepwise reduction in use of lipid-lowering therapy as a function of D19H genotype. Login to comment 155 ABCG8 p.Asp19His Regardless of whether we restricted the follow-up period to the period 1976-1990 (i.e., prior to the advent of statins) or excluded all participants on lipid-lowering therapy during the study, the hazard ratios for symptomatic gallstone disease as a function of D19H genotype were largely unchanged. Login to comment 156 ABCG8 p.Asp19His Together, these results indicate that the increased risk of symptomatic gallstone disease observed in carriers of D19H could not be explained by their lower use of lipid-lowering therapy. Login to comment 158 ABCG8 p.Asp19His Baseline liver parameters, plasma lipid and lipoprotein levels, and use of lipid-lowering therapy as a function of ABCG8 D19H genotype. Login to comment 165 ABCG8 p.Asp19His Although functional studies aimed at testing whether D19H constitutes a gain-of-function variant that increases biliary cholesterol efflux are clearly warranted, a clinically interesting question is whether the putative increase in biliary cholesterol efflux can be counteracted medically. Login to comment 166 ABCG8 p.Asp19His An affirmative answer to this question could resurrect the widely abandoned concept of nonsurgical treatment for gallstones, at least in the subset of D19H-positive patients. Login to comment 170 ABCG8 p.Asp19His In conclusion, ABCG8 D19H is the first genetic variant to predict risk of symptomatic gallstone disease and biliary cancer in the general population. Login to comment 171 ABCG8 p.Asp19His The clinical impact appears to be substantial in that 11% of all symptomatic gallstones and 27% of all biliary cancers in our study can be attributed to D19H genotype. Login to comment